People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $611.8M | 2014 |
| Aerie Pharmaceuticals Inc | — | Biotechnology | Series D+ | $189.6M | $5.2B | 2011 |
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
| Marinus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.4M | $21.0M | 2009 |
| First Aid Beverages, Inc. | — | Other | Series B | $27.4M | $337.8M | 2015 |
| NEXTWAVE PHARMACEUTICALS Inc | — | Pharmaceuticals | Series B | $27.2M | $925.9M | 2011 |
| Vicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $22.0M | $536.9M | 2009 |
ANAND MEHRA at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ANAND MEHRA on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert Cha | 2 | 9 |
| Stephen Tullman | 2 | 7 |
| Neal Walker | 2 | 5 |
| Christopher Powala | 2 | 3 |
| Robert Casale | 2 | 2 |
| Garheng Kong | 1 | 16 |
| Stephen Bloch | 1 | 15 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| Ketan Patel | 1 | 10 |
| Brian Levy | 1 | 8 |
| David Gordon | 1 | 8 |
| Thomas Beck | 1 | 7 |
| Harry H Penner, Jr. | 1 | 6 |
| Christopher M. Cashman | 1 | 6 |
| David Epstein | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| Paul Grint | 1 | 5 |
| Andrew Schiff | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.